What is CNTN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CNTN?

P/E (TTM) is n/a and 52-week range is $1.75 to $6.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CNTN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CNTN?

The company profile lists net income (TTM) near $-121M, EPS (TTM) near $-1.57 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Canton Strategic Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bridgewater, New Jersey, US, 77.1M shares outstanding, ISIN US4327053090 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Canton Strategic Holdings, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 12 full-time employees. The company went IPO on 2022-01-12. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The firm also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.

Employees

Website

www.cantonstrategic.com

IPO

2022-01-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)